Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Trial Profile

Phase II Trial of Combination Immunotherapy in Biochemically Recurrent Prostate Cancer

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Nov 2017

At a glance

  • Drugs CV 301 (Primary) ; MSB 0011359C (Primary) ; Rilimogene galvacirepvec-rilimogene glafolivec (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Nov 2017 Planned initiation date changed from 2 Nov 2017 to 17 Nov 2017.
    • 27 Oct 2017 Planned initiation date changed from 30 Oct 2017 to 2 Nov 2017.
    • 25 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top